CN101365477A - 治疗出血性休克的药物制剂及其缓释胶囊剂或缓释片剂(sequels) - Google Patents

治疗出血性休克的药物制剂及其缓释胶囊剂或缓释片剂(sequels) Download PDF

Info

Publication number
CN101365477A
CN101365477A CNA2006800486507A CN200680048650A CN101365477A CN 101365477 A CN101365477 A CN 101365477A CN A2006800486507 A CNA2006800486507 A CN A2006800486507A CN 200680048650 A CN200680048650 A CN 200680048650A CN 101365477 A CN101365477 A CN 101365477A
Authority
CN
China
Prior art keywords
pro
arg
gly
peptide
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800486507A
Other languages
English (en)
Chinese (zh)
Inventor
P·佩特泽尔鲍尔
R·亨宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrex Medical Research and Development GmbH
Original Assignee
Fibrex Medical Research and Development GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrex Medical Research and Development GmbH filed Critical Fibrex Medical Research and Development GmbH
Publication of CN101365477A publication Critical patent/CN101365477A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2006800486507A 2005-12-23 2006-11-10 治疗出血性休克的药物制剂及其缓释胶囊剂或缓释片剂(sequels) Pending CN101365477A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0206705A AT502987A1 (de) 2005-12-23 2005-12-23 Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
ATA2067/2005 2005-12-23

Publications (1)

Publication Number Publication Date
CN101365477A true CN101365477A (zh) 2009-02-11

Family

ID=37846035

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800486507A Pending CN101365477A (zh) 2005-12-23 2006-11-10 治疗出血性休克的药物制剂及其缓释胶囊剂或缓释片剂(sequels)

Country Status (14)

Country Link
US (1) US7897574B2 (https=)
EP (2) EP1962887B1 (https=)
JP (1) JP2009520696A (https=)
KR (1) KR20080108221A (https=)
CN (1) CN101365477A (https=)
AT (2) AT502987A1 (https=)
AU (1) AU2006326890A1 (https=)
CA (1) CA2634026A1 (https=)
DE (1) DE502006004619D1 (https=)
ES (1) ES2331970T3 (https=)
IL (1) IL192349A0 (https=)
NO (1) NO20083191L (https=)
RU (1) RU2008130413A (https=)
WO (1) WO2007070899A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641908A1 (en) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
JP2010540892A (ja) * 2007-09-24 2010-12-24 ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー 抗炎症活性を有する化合物をスクリーニングする方法
US20130324469A1 (en) * 2010-12-09 2013-12-05 The Brigham And Women's Hospital, Inc. Fibrinogen and kidney damage
TW201718028A (zh) * 2015-10-13 2017-06-01 賽米克Ｉｐ有限責任公司 Ve-鈣黏蛋白結合性生物結合物
JP7506364B2 (ja) * 2019-10-24 2024-06-26 国立大学法人東海国立大学機構 慢性肺疾患／急性呼吸窮迫症候群の治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997844A (en) 1991-02-08 1999-12-07 Diatide, Inc. Technetium-99m labeled peptides for imaging
BR0116122A (pt) 2000-12-12 2003-10-14 Fibrex Medical Res & Dev Gmbh Peptìdeos e/ou proteìnas bem como seu uso para preparar uma composição farmacêutica, terapêutica e/ou preventiva
US20080311103A1 (en) * 2004-03-08 2008-12-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Anti-Inflammatory Peptides and Methods of Use Thereof
AT414097B (de) 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock
DK1691827T3 (da) * 2004-06-25 2009-12-14 Fibrex Medical Res & Dev Gmbh Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock

Also Published As

Publication number Publication date
ATE440282T1 (de) 2009-09-15
KR20080108221A (ko) 2008-12-12
NO20083191L (no) 2008-09-16
AU2006326890A1 (en) 2007-06-28
EP1962887A2 (de) 2008-09-03
EP2110136A2 (de) 2009-10-21
US20090005310A1 (en) 2009-01-01
JP2009520696A (ja) 2009-05-28
EP2110136A3 (de) 2010-01-27
DE502006004619D1 (de) 2009-10-01
RU2008130413A (ru) 2010-01-27
EP1962887B1 (de) 2009-08-19
ES2331970T3 (es) 2010-01-21
WO2007070899A3 (de) 2007-10-04
AT502987A1 (de) 2007-07-15
CA2634026A1 (en) 2007-06-28
US7897574B2 (en) 2011-03-01
WO2007070899A2 (de) 2007-06-28
IL192349A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
Ames et al. The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome.
TWI801331B (zh) 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
KR20140011372A (ko) 인공 표면과의 접촉을 포함하는 의료 시술에 투여하기 위한 인자 ｘｉｉ 억제제
US10617745B2 (en) Methods for preventing post-operative complications of cardiopulmonary surgery
SABA et al. Lung vascular permeability after reversal of fibronectin deficiency in septic sheep: correlation with patient studies
CN101365477A (zh) 治疗出血性休克的药物制剂及其缓释胶囊剂或缓释片剂(sequels)
Donahue et al. Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass
EP1691827B1 (de) Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
JP2016506920A (ja) 止血組成物
JP2017508806A (ja) 出血性疾患の治療における止血を改善するためのヒトプロトロンビン及び活性化第ｘ因子の組成物
TW200529870A (en) Therapeutic use of factor XI
JP5268638B2 (ja) 新規局所用抗出血剤としての活性型第Ｘ因子（ＦＸａ）の刺激因子
MX2008008324A (en) Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms
Vu et al. A review of alkaline phosphatase in preventing systemic inflammation after cardiac surgery
US20030220253A1 (en) Inhibitors for use in hemostasis
CA2967183A1 (en) Compositions and methods for treating post-operative complications of cardiopulmonary surgery
CN119684441B (zh) 一种衍生多肽pm6及其在抗血栓中的应用
US20230285523A1 (en) Use of elafin in the treatment of covid-19
JP2012519674A (ja) フィブリノーゲンの新規な使用
RU2813699C2 (ru) Плазминоген для лечения и профилактики микротромбоза
US7772371B2 (en) Stimulators of Factor X activated (FXa) as new topical antihemorrhagic agents
AT501263B1 (de) Pharmazeutische zubereitung zur behandlung von schock
ADANIR et al. The Levels of Von Willebrand Factor in Adult Patients with Familial Mediterranean Fever and it is Relationship with Platelet Activation
US20170035863A1 (en) Compositions Comprising Variegin
Pimanda Control of von Willebrand factor multimer size

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090211